Introduction

Publicationsback to News>

Keystone 2012

  • Rosa: Virtual Combination Therapy in Virtual NSCLC Tumor Cells Supports Strategic ... Decisions. (Abstract)

ASCPT 2012

  • Pfizer:Role of Myostatin Pathway in Muscle Growth...Preclinical and Clinical...PK/PD Modeling (Abstract)

JCTR 2011

  • Duke U, Martek Biosciences, Duke Clin Res Inst, Duke-NUS-Singapore: Jiang W, Oken H, Fiuzat M, Shaw LK, Martsberger C, Kuchibhatla M, Kaddurah-Daouk R, Steffens DC, Baillie R, Cuffe M, Krishnan R, O'Connor C; for the SADHART-CHF Investigators. Plasma Omega-3 Polyunsaturated Fatty Acids and Survival in Patients with Chronic Heart Failure and Major Depressive Disorder. J Cardiovasc Transl Res 2011 (in press)

AAPS 2011

  • Rosa:Pediatric PK Modeling using AMS Data and PhysioPD™ Modeling of Ursodiol in a Neonate...Trial (poster)

PLoS One 2011

  • Duke U, North Carolina State U, U of Idaho, Lipomics Technologies, SRI International, Children's Hosp Oakland Res Inst: Kaddurah-Daouk R, Baillie RA, Zhu H, Zeng ZB, Wiest MM, Nguyen UT, Wojnoonski K, Watkins SM, Trupp M, Krauss RM. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS One. 2011;6(10):e25482. (opensource)

ICSB 2011

  • Rosa:Whether, How Much, and Why: Integrating Modeling and Systems Biology...in Neonates (poster)

PAGE 2011

  • Rosa: Comparison of NLME and Mechanistic Physiological Modeling... Examples in Drug Discovery... (poster)

PKPD Summit 2011

  • Pfizer: Creating and Using a Physiological Model to Evaluate GPR119 Agonism as a Diabetes... (slides)

ACoP 2011

  • Pfizer: Impact of Modeling on GPR119 Agonist Development (Abst, poster)
  • MediciNova: PK and PD Modeling Supports Development of MN-221...COPD (Abst, poster)
  • MediciNova: PK and PD Modeling and Simulation Support Development of MN-221... Asthma (Abst, pstr)
  • Vitalea: Accelerator Mass Spectrometry Enables Pediatric PK/PD Analysis in a Neonate... (Abst, pstr)
  • Lithera: Modeling Supports Determination of First-In-Human Dosing and Rapid...LIPO-102 (Abst, pstr)
  • Rosa: Qualifying Mechanistic Physiological Models for Use in Pharmaceutical Discovery and... (Abst, pstr)

Metabolomics 2010

  • Duke U, Lipomics Technologies, North Carolina State U, Children’s Hosp Oakland Res Inst: Kaddurah-Daouk R, Baillie RA, Zhu H, Zeng ZB, Wiest MM, Nguyen UT, Watkins SM, Krauss RM. Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study. Metabolomics. 2010 Jun;6(2):191-201. (opensource)

ASPCT 2010

  • Vitalea: Evaluation of Ursodiol Pharmacokinetics in Neonates Using AMS (Abstract, poster)

ChiDot 2010

  • MediciNova: PK/PD Modeling of MN-221 for COPD and Acute Asthma (poster)
  • Rosa: Modeling Glucose Metabolism in Diabetes (poster)

CHEST 2010

  • MediciNova: PK and PD Modeling and Simulation Support the Novelty of MN-221... Asthma (Abst, poster)
  • MediciNova: PK and PD of MN 221, a Novel Highly-Selective Beta2-Adrenergic...COPD (Abst, poster)

ACoP 2009

  • Rosa: PK Modeling, Simulation, and Scaling of Adult and Pediatric Data to Support International... (poster) 

PAGE 2008

  • Merck: Alteration of glucose and insulin regulatory networks in Type 2 diabetes mellitus (poster)

Bey. Genome 2008

  • Rosa: Validation of Physiologic Models and Analysis of Uncertainty (poster)

ACoP 2008

  • Rosa: Validation and Uncertainty Analysis of Physiologic Models (poster)
  • Rosa: A Simple Method for Approximating Population Pharmacokinetic Parameters (poster)

ADA 2008

  • Rosa: A Computational Model of Hepatic Glucose Metabolism (Abstract)

IRA 2008

  • Rosa: Chronic Inflammation in Asthma Airway Remodeling (poster)

NIGMS 2008

  • Rosa: Validation and Uncertainty Analysis of Physiological Models (Abstract)